ARS Pharmaceuticals, Inc.

    Jurisdiction
    United States
    ISIN
    US82835W1080 (SPRY)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    €12.81 ∞% undervalued
    Financial strength (Piotroski F-Value)
    3 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    4 / 7

    Profile

    Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. Read full profile

    Fundamentals

    Net revenue
    €95.82M
    Gross margin
    78.0%
    EBIT
    -€50.62M
    EBIT margin
    -52.8%
    Net income
    -€40.96M
    Net margin
    -42.7%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €188.72M +97.0% -€61.47M +50.1%
    €325.42M +72.4% €21.78M -135.4%
    €500.32M +53.7% €150.36M +590.2%

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Lowenthal Richard E PRESIDENT AND CEO -50K $14.49 -$724.50K
    Scott Kathleen D. Chief Financial Officer -13K $15.00 -$187.50K
    Tanimoto Sarina CHIEF MEDICAL OFFICER -50K $14.08 -$704.00K

    Earnings Calls

    Earnings Calls

    Latest earnings call: August 13, 2025 (Q2 2025)

    Add to watchlist

    Notifications